Last updated: February 15, 2026
What is the current market landscape for NDC 51672-1303?
NDC 51672-1303 is marketed as Tarpeyo (budesonide), a corticosteroid indicated for the treatment of adult patients with immunoglobulin A (IgA) nephropathy. It was approved by the U.S. Food and Drug Administration (FDA) in July 2021.
The approval marked Tarpeyo as a targeted therapeutic option for IgA nephropathy, a condition affecting approximately 150,000 to 180,000 people in the U.S. (source: CDC). The drug’s initial launch was confined to certain specialties, with broader distribution expected over the next 12-24 months.
What is the competitive landscape?
Key competitors
- Rituxan (rituximab): Off-label use; estimated global sales of ~$3.1 billion annually.
- Steroid therapies: Including oral prednisone and methylprednisolone, traditionally used but associated with toxicity.
- Other emerging treatments:
| Drug Name |
Status |
Indications |
Estimated Launch Date |
| Bardoxolone (Reata Pharmaceuticals) |
Under review |
Various kidney diseases |
N/A |
| Obolarsen (Ionis Pharmaceuticals) |
Clinical phase |
IgA nephropathy |
2024-2026 |
Market entry considerations
- The initial exclusivity of Tarpeyo limits immediate competition.
- The orphan drug designation facilitates price premium and extended market exclusivity until 2031.
- Use of corticosteroid therapies outside FDA-approved scope affects market penetration.
What are the price projections?
Current pricing
- Launch Price: Estimated at approximately $36,000-$40,000 per year per patient, based on pricing of similar glucocorticoids ([1], [2]).
- Reimbursement: Coverage through Medicare, Medicaid, commercial payers varies; initial reimbursement rates are projected at 80-85% of list price.
Market penetration assumptions
- Year 1 (2023): Sales estimated around $50 million due to limited initial uptake.
- Year 2 (2024): Sales increase as awareness and prescriptions grow, reaching approximately $150 million.
- Year 3 (2025): Market expansion and broader physician adoption could push sales toward $300 million.
Price sensitivity analysis
| Scenario |
Price per patient |
Yearly revenue estimate |
Assumptions |
| Base case |
$38,000 |
$150 million |
4,000 patients in year 2 |
| High-price scenario |
$40,000 |
$160 million |
Slight market expansion |
| Price discount scenario |
$36,000 |
$135 million |
Discounts or formularies limit access |
External factors influencing prices
- Rebate negotiations and insurance carve-outs may reduce net revenue.
- Market competition and patent or exclusivity periods could permit sustainable pricing for 5-7 years.
What are the key factors impacting future market value?
- Regulatory status: Continued exclusivity enhances pricing power.
- Physician acceptance: Awareness of efficacy will determine prescription volume.
- Healthcare policies: Insurance reimbursement policies could either facilitate or impede adoption.
- Emerging therapies: Development of alternative treatments may cap market share growth.
What are projected risks?
- Delays in broader approval or position as specialty medication may slow adoption.
- Competition from biosimilars or other novel agents.
- Cost containment pressures from payers aiming to limit expenditures on high-cost therapies.
Key Takeaways
- NDC 51672-1303 (Tarpeyo) is a newly approved corticosteroid for IgA nephropathy with initial launch prices around $38,000 per year.
- Sales are projected to hit $150-$300 million by 2025, driven by increased prescription volume.
- Pricing is subject to payer negotiations, discounts, and competition, with potential for price stability due to orphan designations and exclusivity.
- Market growth depends on physician adoption, insurance coverage, and emerging competition.
- Long-term revenue projections remain contingent on regulatory developments, patent life, and market dynamics.
FAQs
1. How does Tarpeyo compare to existing treatments?
Tarpeyo offers targeted delivery of budesonide for IgA nephropathy, potentially reducing systemic corticosteroid side effects compared to oral steroids. Existing treatments like prednisone have toxicity risks that Tarpeyo aims to mitigate.
2. What are the main barriers to market expansion?
Barriers include limited initial distribution channels, payer reimbursement challenges, off-label use of competing therapies, and the drug’s status as a niche indication.
3. When will broader market penetration occur?
Broader market adoption is expected over 12-24 months post-launch, as prescriber awareness increases and insurance coverage expands.
4. What are the patent and exclusivity statuses?
Tarpeyo has orphan drug designation, which provides market exclusivity until 2031, assuming no patent challenges or regulatory changes.
5. What is the potential for price erosion?
Long-term price erosion is possible due to generic competition after patent expiry, biosimilar entries, or competitive innovations emerging within 5-7 years.
References
[1] Bloomberg Intelligence, 2022. U.S. corticosteroid therapy pricing trends.
[2] IQVIA National Sales Perspective, 2022. Biopharma market data.
[3] CDC. "Chronic Kidney Disease Surveillance," 2021.
